Literature DB >> 21272070

Exclusive enteral nutrition in the treatment of children with Crohn's disease in Sweden: a questionnaire survey.

Josefin M Gråfors1, Thomas H Casswall.   

Abstract

AIM: The general use of exclusive enteral nutrition (EEN) as therapy for children with Crohn's disease (CD) in Sweden has not previously been studied. Thus, the aim of this study was to investigate how EEN is used as therapy in Sweden for children with CD.
METHODS: A questionnaire was sent to all 37 paediatric units in Sweden that treat children with inflammatory bowel disease.
RESULTS: The response rate was 78%, which covers nearly 90% of Sweden's paediatric population between 0 and 17 years of age. Ninety-six per cent of the units used EEN as a treatment option for children with CD, and 65% of the units used EEN as their primary therapy in newly diagnosed CD. The standard duration of EEN was 6 weeks, but the questionnaire revealed a span of 4-8 weeks. The use of polymeric formula was just as common as a combination of polymeric and elemental formulas. Fifty-seven per cent used oral nutrition supplements, and 81% allowed some extent of concomitant feeding, the addition of food and fluids, during EEN. All units used enteral nutrition to some extent as maintenance therapy after EEN was discontinued.
CONCLUSIONS: In Sweden, EEN is used as therapy for children with Crohn's disease (CD), but the EEN protocols vary as to choice of formula and type of food and fluids allowed during EEN. Standardized EEN protocols would enable multicentre studies in Sweden, with the objective of investigating how EEN treatment can be improved and employed in the most efficient way.
© 2011 The Author(s)/Acta Paediatrica © 2011 Foundation Acta Paediatrica.

Entities:  

Mesh:

Year:  2011        PMID: 21272070     DOI: 10.1111/j.1651-2227.2011.02178.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  8 in total

Review 1.  An update of the role of nutritional therapy in the management of Crohn's disease.

Authors:  Moftah H Alhagamhmad; Andrew S Day; Daniel A Lemberg; Steven T Leach
Journal:  J Gastroenterol       Date:  2012-06-15       Impact factor: 7.527

Review 2.  Exclusive enteral nutrition in children with Crohn's disease.

Authors:  Andrew S Day; Robert N Lopez
Journal:  World J Gastroenterol       Date:  2015-06-14       Impact factor: 5.742

3.  Epithelial CaSR deficiency alters intestinal integrity and promotes proinflammatory immune responses.

Authors:  Sam X Cheng; Yaíma L Lightfoot; Tao Yang; Mojgan Zadeh; Lieqi Tang; Bikash Sahay; Gary P Wang; Jennifer L Owen; Mansour Mohamadzadeh
Journal:  FEBS Lett       Date:  2014-05-17       Impact factor: 4.124

4.  The Protective Effects of Exclusive Enteral Nutrition Formulas on Growth Factor Expression and the Proximal Tibial Epiphyseal Growth Plate in a TNBS-Induced IBD Rat Model.

Authors:  Jieru Shi; Zhiheng Huang; Yuhuan Wang; Ying Huang
Journal:  Dig Dis Sci       Date:  2015-02-24       Impact factor: 3.199

5.  Therapeutic Efficacy of Oral Enteral Nutrition in Pediatric Crohn's Disease: A Single Center Non-Comparative Retrospective Study.

Authors:  Hyun Jin Kim; Young Kim; Jin Min Cho; Seak Hee Oh; Kyung Mo Kim
Journal:  Yonsei Med J       Date:  2016-09       Impact factor: 2.759

6.  Exclusive enteral nutrition in children with inflammatory bowel disease: Physician perspectives and practice.

Authors:  Shaun S C Ho; Andrew S Day
Journal:  JGH Open       Date:  2018-12-12

Review 7.  Exclusive Enteral Nutrition in Adult Crohn's Disease: an Overview of Clinical Practice and Perceived Barriers.

Authors:  Roberto de Sire; Olga Maria Nardone; Anna Testa; Giulio Calabrese; Anna Caiazzo; Fabiana Castiglione
Journal:  Clin Exp Gastroenterol       Date:  2021-12-29

8.  Implementation of exclusive enteral nutrition in pediatric patients with Crohn's disease-results of a survey of CEDATA-GPGE reporting centers.

Authors:  Sarah Peters; Serdar Cantez; Jan De Laffolie
Journal:  Mol Cell Pediatr       Date:  2022-04-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.